LETTERS TO THE EDITOR   

Minerva Medica 2021 April;112(2):310-2

DOI: 10.23736/S0026-4806.19.06236-0

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Efficacy and safety of cyclophosphamide, doxorubicin, vincristine, and prednisone regimen with pegylated liposomal doxorubicin±rituximab in treating diffuse large B-cell lymphoma

Yuhuan GAO ¹, Yan XIE ², Lihong LIU ¹, Hongwei XUE ³, Ming HOU ⁴, Mingzhi ZHANG ⁵, Zeping ZHOU ⁶, Pengxiang GUO ⁷, Hongxia YAO ⁸, Zonghong SHAO ⁹, Xiaobao XIE ¹⁰, Jun ZHU ² ✉

¹ Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China; ² Department of Lymphoma Medicine, Beijing Cancer Hospital, Beijing, China; ³ Department of Oncology, Affiliated Hospital of Medical College of Qingdao University, Qingdao, China; ⁴ Department of Hematology, Qilu Hospital, Shandong University, Jinan, China; ⁵ Department of Oncology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; ⁶ Department of Hematology, Second Affiliated Hospital of Kunming Medical University, Kunming, China; ⁷ Department of Hematology, Guizhou People’s Hospital, Guizhou, China; ⁸ Department of Hematology, Hainan Provincial People’s Hospital, Hainan, China; ⁹ Department of Hematology, General Hospital of Tianjin Medical University, Tianjin, China; ¹⁰ Department of Hematology, Changzhou First People’s Hospital, Changzhou, China